Trailer For Pixar's Sci-Fi Comedy HOPPERS Turns Animal Communication Into a Wild Ride — GeekTyrant
The film follows Mabel (voiced by Piper Curda), who becomes the first human to transfer her consciousness into a robotic animal prototype. The goal is to infiltrate the animal kingdom and learn what makes our furry friends tick.
Think Avatar , but swap blue aliens for adorable, photorealistic critters, and toss in Pixar's signature heart and humor.
The movie comes from Daniel Chong, creator of We Bare Bears , whose quirky, heartfelt style shines through in the trailer. In a statement, Chong explained:
'In Hoppers, the question we're answering is: 'What if we could understand and communicate with the animal world?' Our main character, Mabel, gets to discover the animal kingdom as an animal, which can be weird and often hilarious.
'Mabel undercover in the animal world leads to a wild, roller coaster ride of a movie, with all the heart you expect from a classic Pixar film. It's going to be so much fun to watch in the theater; I can't wait for everyone to see it.'
The voice cast also includes Bobby Moynihan ( We Bare Bears ) and Jon Hamm ( Top Gun: Maverick ). The trailer teases some clever comedy built around the lifelike robot blending in with unsuspecting animals, and the chaos that comes when nature's rules start to bend.
Will this experiment bridge the gap between humans and animals, or completely upend the natural order? We'll find out when Hoppers hops into theaters on March 6, 2026.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results
MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 6, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID: TECHQ4 Webcast: A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11159590. The replay will be available from 11:00 a.m. CDT on Wednesday, August 6, 2025, until 11:00 p.m. CDT on Saturday, September 6, 2025. About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development 612-656-4416 View original content to download multimedia: SOURCE Bio-Techne Corporation Sign in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy
CRANBURY, N.J., July 17, 2025--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A601, the Company's investigational adeno-associated virus (AAV)-based gene therapy for the treatment of PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death. RMAT designation was granted based on positive safety and efficacy data from the Phase 1 RP-A601 clinical trial and will provide the benefits of added intensive FDA guidance and expedited review through the program's development. "The FDA's RMAT designation for RP-A601 represents a meaningful advancement for Rocket and for patients living with PKP2-ACM, a life-threatening genetic heart disease characterized by ventricular arrhythmias and sudden cardiac death," said Kinnari Patel, PharmD, MBA, President, Head of R&D of Rocket Pharmaceuticals. "This marks the fifth RMAT designation in our history and underscores our commitment to developing potentially curative gene therapies for patients with rare and inherited cardiovascular diseases. The early clinical data for RP-A601 are highly encouraging, and we look forward to continued collaboration with the FDA throughout the program's development." RMAT designation was established under the 21st Century Cures Act to expedite the development and review of promising therapeutic candidates, including gene therapies, that are intended to treat, modify, reverse or cure a serious or life-threatening disease. RMAT designation provides several benefits, such as early interactions with the FDA, including discussions on surrogate or intermediate endpoints that could potentially support accelerated approval and satisfy post-approval requirements, and potential priority review of a product's biologics license application (BLA). Preliminary results from the ongoing Phase 1 clinical trial of RP-A601 presented at the 2025 Annual Meeting of the American Society of Gene and Cell Therapy demonstrated encouraging early safety and efficacy. All three adult patients treated with a single dose of RP-A601 (8x10¹³ GC/kg) showed increased PKP2 protein expression, including 110% and 398% increases in the two patients with low baseline levels, as well as improved desmosomal integrity with relocalization of key structural proteins. Improvements or stabilization were observed across clinically meaningful endpoints, including right ventricular function, ventricular arrhythmias, and quality of life highlighted by increases of 34–41 points in KCCQ-12 scores and improvements in NYHA classification from Class II to Class I. The safety profile was favorable, with RP-A601 generally well-tolerated, no dose-limiting toxicities, and most adverse events being mild or moderate and self-limited. About RP-A601RP-A601 is an investigational gene therapy for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). RP-A601 consists of a recombinant adeno-associated serotype rh74 capsid containing a functional version of the human PKP2 transgene ( which is administered as a single intravenous (IV) infusion. RP-A601 is being investigated as a one-time, potentially curative gene therapy treatment that may improve survival and quality of life for patients affected by PKP2-ACM. Rocket holds Fast Track designation in the U.S. and Orphan Drug designation in the U.S. and Europe for the program. About PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM)PKP2-ACM is an inherited heart disease caused by mutations in the PKP2 gene and characterized by life-threatening ventricular arrhythmias, cardiac structural abnormalities, and sudden cardiac death. PKP2-ACM affects approximately 50,000 adults and children in the U.S. and Europe. Patients living with PKP2-ACM have an urgent unmet medical need, as current medical, implantable cardioverter defibrillator (ICD), and ablation therapies do not consistently prevent disease progression or arrhythmia recurrence, are associated with significant morbidity including inappropriate shocks and device and procedure-related complications, and do not address the underlying pathophysiology or genetic mutation. About Rocket Pharmaceuticals, Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket's innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives. Rocket's adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage clinical program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, and an early-stage clinical program for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death. Rocket has also received IND clearance for its AAV-based gene therapy for BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles. Rocket's lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. For more information about Rocket, please visit and follow us on LinkedIn, YouTube, and X. Rocket Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements concerning Rocket's future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as "could," "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket's expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket's ongoing and planned clinical trials, the expected timing and outcome of Rocket's regulatory interactions and planned submissions, including the timing and outcome of the FDA's review of the additional CMC information that Rocket will provide in response to the FDA's request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket's ability to establish key collaborations and vendor relationships for its product candidates, Rocket's ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket's ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket's ability to transition to a commercial stage pharmaceutical company, and Rocket's expectation that its cash, cash equivalents and investments will be sufficient to fund its operations into 2027. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket's competitors' activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket's ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket's ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket's ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-K for the year ended December 31, 2024, filed February 27, 2025 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts Investors Meg Dodgemdodge@ Media Kevin Giordanomedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Nepo is the new normal: How the kids of Hollywood A-listers started getting real and stopped fighting their family name
If you can't escape the shadow, step into it. That's the new way of the Hollywood nepo baby. Take Jack Henry Robbins, son of Susan Sarandon and Tim Robbins, for example. He just landed a Hulu comedy series, aptly titled Nepo Baby, based on the viral character he created satirizing his own life as the child of celebrities. The series will riff on the nepo baby phenomenon popularized by New York magazine's 2022 cover story, which spotlighted how the children of stars often have a head start in Hollywood compared to those without connections. Jack, 36, wrote on Instagram that the character he created "was born from my deepest insecurity." However, embracing the role of "the world's worst nepo baby" — with assists from his parents and Steven Spielberg's daughter Sasha, who appeared in the social media series — "changed my life." Ireland Baldwin, daughter of Alec Baldwin and Kim Basinger and an aspiring screenwriter, was quick to quip in the comments section, "I'm available." We've entered a nepo baby era that sees the latest crop of famous offspring embrace their lineages with a healthy dose of self-awareness. Like Ava Phillippe, daughter of Reese Witherspoon and Ryan Phillippe, who recently got behind the "holy freakin' airball" TikTok trend, where people share an incorrect assumption followed by a humblebrag. The brand ambassador/model/aspiring actress flexed about her mother's role as Elle Woods in Legally Blonde. The nepos, it seems, are exhibiting signs of acceptance, marking a noticeable shift from the Hollywood "nepo-verse" strongly opposing the label not so long ago. A cool nickname Hollywood has always been a famous family business. Michael Douglas, Jane Fonda, Jamie Lee Curtis, Ben Stiller, Gwyneth Paltrow and Robert Downey Jr. have last names that carry weight in the entertainment industry, with the pedigree to back it up. Their lineages were never a secret — nor were those of Kate Hudson, Angelina Jolie or Isabella Rossellini. But amid a broader cultural reckoning with privilege and access, a more blinding spotlight was shone on the connections of the younger crop of connected stars. Lily-Rose Depp, Jack Quaid, Zoë Kravitz, Maya Hawke, Maude Apatow, Kendall Jenner, Hailey Bieber and Kaia Gerber have all been dubbed "nepo babies" for their A-list relations. Yes, talent can run in a family, but so can connections. While these young stars have chops, they also have built-in access to agents and casting directors that the typical aspiring performer doesn't. Even if a nepo baby doesn't use a parent's connections directly, their last name alone provides intrigue, inviting them in the door that's closed for most everyone else. That's something not offered to the typical aspiring actor who's traveled to Hollywood with nothing. Are they under harsher scrutiny than the nepo babies before them? Definitely. In this age of 24/7 news coverage and social media, audiences are aware of their connections and New York magazine gave that awareness a name (or 'ugly moniker,' as Paltrow dubbed it). After all, culturally, entertainment consumers bear some blame for the public's long-running interest in star kids. Since some of them were born, they were staked out by paparazzi at the playground with their images filtered to celebrity magazines and websites. We've long been fascinated by them. Plus, we're in an era of Hollywood where originality is increasingly rare. Most movies are largely sequels, franchises or based on a popular toy, book or video game. In this risk-averse industry, the nepo baby fits right in. Instead of being an "unknown" talent, they come in already familiar to audiences. We've watched many of them grow up, seen them on red carpets with their famous parents. There's no need for introductions. Cue the outrage How the nepo babies responded to the branding was of their own successful or failed PR plan. At this point, practically everyone has been asked about it, but soon after the publication of the New York cover story, Lily-Rose Depp, the actress daughter of Johnny Depp and Vanessa Paradis, faced criticism for not "getting it." "People are going to have preconceived ideas about you or how you got there, and I can definitely say that nothing is going to get you the part except for being right for the part," The Idol actress told Elle in 2022. "The internet cares a lot more about who your family is than the people who are casting you in things. Maybe you get your foot in the door, but you still just have your foot in the door. There's a lot of work that comes after that." Kendall Jenner, the model daughter of Kris Jenner and Caitlyn Jenner, was also called out of touch after she said that while she's "one of the luckiest people on the planet to be able to live the life that I live. … I do think that it's challenging for me a lot more than it's not." Zoë Kravitz, the actress/director daughter of Lenny Kravitz and Lisa Bonet, was also called tone deaf for her comments about it being "completely normal for people to be in the family business. It's literally where last names came from. You were a blacksmith if your family was, like, the Black family." Theater Camp star Ben Platt, son of Legally Blonde producer Marc Platt, wouldn't even answer a question about being a nepo baby in 2023. His publicist intervened. Embracing the bloodline Amid the nepo backlash, Hailey Bieber — daughter of Stephen Baldwin and now wife of Justin Bieber — leaned into the controversy by wearing a shirt proudly bearing the label in 2023. She later told the Sunday Times, "That was me being, like, 'I'm very aware of the situation [and] I'm going to wear it loud and proud because you are already labeling me as such and it's true.'" Over the last year, as the nepo-ness of it all has settled, there's been more of an embrace of it by some. While Dakota Johnson, daughter of Don Johnson and Melanie Griffith, finds the whole conversation "annoying," "boring" and "lame," she did playfully parody it on Saturday Night Live, offering herself up as the punchline. She also recently talked about how her dad cut her off when she didn't get into Juilliard and she had to pound the pavement a bit. "It was hard to make money. There were a few times when I'd go to the market and not have money in my bank account or not be able to pay rent." The granddaughter of Hollywood royalty Tippi Hedren added, "I'd have to ask my parents for help." Patrick Schwarzenegger has called the label "frustrating" and talked about the "hundreds of rejected auditions" he had before landing his revealing White Lotus role. But then in June, he did an about-face, leaning into his scion status by doing a joint Variety interview with his dad and discussing — yes — nepotism. "There were times earlier in my career where I was wondering, does it make sense to go under an alias?" Patrick, son of Maria Shriver, admitted. Arnold said he was surprised to learn how difficult a time Patrick had because of his last name, saying, "To me, the name 'Schwarzenegger' always meant a big plus." Allison Williams, daughter of newsman Brian Williams, is also among the more self-aware nepo babies. The Girls alum told the Guardian, "Aside from all the many layers of privilege, high on the list is the fact that I could pursue a career in acting without being worried that I wasn't going to be able to feed myself." Kaia Gerber, the actress/model daughter of Cindy Crawford and Rande Gerber, told WSJ last year, "I don't think it's a topic that will go away, so I've clearly reached a point of acceptance. I personally am very aware of all the wonderful things it has done for me, and I would never, ever say anything negative about it, because that is my truth about it." Her nepo baby boyfriend, Lewis Pullman, the son of Bill Pullman, also acknowledged that his father's fame allowed him many chances to "get comfortable in front of a camera" because it took him a long time to get there. However, part of it was trying to live up to his father's reputation. The Thunderbolts* actor said, "I felt a lot of pressure to fill his shoes. Once I realized that it was an impossible pair of shoes to fill, I kind of found a sense of relief in knowing that if there was any future for me in film that it would be by doing it my own way and trying to blaze my own trail." 'We're still talking about it' After their early comments on the topic weren't well-received, nepo babies adopted a new PR strategy. They've been owning the label more, so they're less weaponized by it. Besides, nearly three years after the New York article came out, the conversation about nepotism in Hollywood isn't going anywhere — just ask the guy who wrote the story. "We definitely knew we were going to cause a stir when we published the story," Vulture features writer Nate Jones tells Yahoo. "You don't Photoshop celebrities' heads onto babies without thinking it'll have some impact." "As far as 2025 goes," he continues, "I don't know if I was thinking that far ahead. But it makes sense that we're still talking about it, because this is a situation that can never really be resolved. On an individual level, nobody is actually doing anything wrong: It's not wrong to want to go into the same field as your parents, or to want your child to follow in your footsteps. It's only when you zoom out to the macro level that it becomes this conversation about wealth and privilege. And obviously structural inequality hasn't gone away in just three years, so it makes sense there's still some resentment towards them." Jones says he's been heartened to see some celebrities start to embrace it. "I feel like there was some hand-wringing in the nepo community after our story was published, like: What are we supposed to do? And I think that a few of them have started to model the best way to handle it, which is to be up front about it," he says. "You've just got to accept it and not be defensive. Because it's the being defensive that really brings the knives out." Jones says it's been "hard not to keep up with" the cultural conversation around nepo babies, "especially because a lot of very kind friends and acquaintances have the misconception that I invented the term [and] send me a link anytime it comes up." However, while he helped popularize the term, he didn't coin it — and he doesn't want it becoming part of his identity either. "Just like a nepo baby doesn't want to only be known as a nepo baby, I don't want to become the 'nepo baby guy,'" Jones says. "After the story blew up, I would get people asking me if I wanted to write a nepo baby book, and that was a no from me. I feel like I've said all I have to say on the subject. Or, 'almost all,'" he says. "I did respond to you, after all." But the conversation isn't fading, it's shifting. These stars didn't choose the nepo life and they're not fighting the label as hard as they once did. And with Hollywood still making space for them, why would they? Solve the daily Crossword
